Literature DB >> 8141117

Changes in longevity and causes of death among persons with hemophilia A.

T L Chorba1, R C Holman, T W Strine, M J Clarke, B L Evatt.   

Abstract

To examine recent changes in longevity and the causes of death among persons with hemophilia A, we evaluated death certificate data for persons who died in the United States from 1968 through 1989 and had hemophilia A or congenital Factor VIII disorder (ICD code 286.0) listed on the death certificate as one of the multiple causes of death. Multiple-cause-of-death mortality data for the United States from 1968 to 1989 were examined to compare death rates by year, focusing on death rates and causes of death for 1979-1981, 1983-1985, and 1987-1989. Gender, age group, race, geographic region, and median age at death of persons with hemophilia A and human immunodeficiency virus (HIV)-related disease listed as a cause of death were compared with those with hemophilia A without HIV-related disease. From 1968 through 1989, 2,792 hemophilia A deaths were reported. The death rate increased from 0.5 to 1.3 per 1,000,000 persons. From 1979-1981 through 1987-1989, mortality increased in all age groups above 9 years of age and age at death shifted markedly to lower ages. Median age at death decreased from 57 years in 1979-1981 to 40 years in 1987-1989. The percentage of deaths due to hemorrhage or diseases of the circulatory system decreased markedly as the result of the increase in deaths associated with HIV infection or infections other than HIV infection. Spread of HIV-1 infection in persons with hemophilia A has disrupted the reduction in mortality seen with factor replacement therapy, implementation of home care, and use of comprehensive hemophilia treatment centers. It is hoped that advances in the care of HIV-infected persons will improve survival in the hemophilia community.

Entities:  

Mesh:

Year:  1994        PMID: 8141117     DOI: 10.1002/ajh.2830450204

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Twenty five years of HIV infection in haemophilic men in Britain: an observational study.

Authors:  Caroline A Sabin; Andrew N Phillips; Thynn Thynn Yee; Anja Griffioen; Christine A Lee
Journal:  BMJ       Date:  2005-09-16

Review 2.  The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.

Authors:  Hector E Castro; María Fernanda Briceño; Claudia P Casas; Juan David Rueda
Journal:  Indian J Hematol Blood Transfus       Date:  2012-11-04       Impact factor: 0.900

3.  Commentary: non-HIV hypotheses must be studied more carefully.

Authors:  P Duesberg
Journal:  BMJ       Date:  1996-01-27

4.  Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report.

Authors:  Xing-Yu Lin; Zhi-Guang Yang; Peng Zhang; Yun-Peng Liu; Cheng-Xiang Wang; Guo-Guang Shao
Journal:  Oncol Lett       Date:  2015-09-17       Impact factor: 2.967

Review 5.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

6.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.

Authors:  Tom Bowen; Marco Cicardi; Henriette Farkas; Konrad Bork; Hilary J Longhurst; Bruce Zuraw; Emel Aygoeren-Pürsün; Timothy Craig; Karen Binkley; Jacques Hebert; Bruce Ritchie; Laurence Bouillet; Stephen Betschel; Della Cogar; John Dean; Ramachand Devaraj; Azza Hamed; Palinder Kamra; Paul K Keith; Gina Lacuesta; Eric Leith; Harriet Lyons; Sean Mace; Barbara Mako; Doris Neurath; Man-Chiu Poon; Georges-Etienne Rivard; Robert Schellenberg; Dereth Rowan; Anne Rowe; Donald Stark; Smeeksha Sur; Ellie Tsai; Richard Warrington; Susan Waserman; Rohan Ameratunga; Jonathan Bernstein; Janne Björkander; Kristylea Brosz; John Brosz; Anette Bygum; Teresa Caballero; Mike Frank; George Fust; George Harmat; Amin Kanani; Wolfhart Kreuz; Marcel Levi; Henry Li; Inmaculada Martinez-Saguer; Dumitru Moldovan; Istvan Nagy; Erik W Nielsen; Patrik Nordenfelt; Avner Reshef; Eva Rusicke; Sarah Smith-Foltz; Peter Späth; Lilian Varga; Zhi Yu Xiang
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

7.  Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.

Authors:  C D Porada; C Sanada; C R Long; J A Wood; J Desai; N Frederick; L Millsap; C Bormann; S L Menges; C Hanna; G Flores-Foxworth; T Shin; M E Westhusin; W Liu; H Glimp; E D Zanjani; J N Lozier; V Pliska; G Stranzinger; H Joerg; D C Kraemer; G Almeida-Porada
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

8.  Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review.

Authors:  Tammuella Chrisentery Singleton; Matthew Keane
Journal:  Ochsner J       Date:  2012

Review 9.  Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV.

Authors:  P H Duesberg
Journal:  Genetica       Date:  1995       Impact factor: 1.082

10.  Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016.

Authors:  Augusto Hasiak Santo
Journal:  Hematol Transfus Cell Ther       Date:  2020-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.